Report: sanofi-aventis: Pipeline, Products, Performance, Potential TOC

Principal Operating Results Latest Results

EXECUTIVE SUMMARY

Introduction
- Current Growth Drivers
- Future Growth Drivers
Financial Performance 2005
- Sales and Market Position
- Income
  - Sales, Costs and Operating Income, 2005
  - Operating Income By Business Area
  - Operating Income By Geographical Area
- Expenditure
  - Restructuring Costs
  - Other Expenses
  - Capital Expenditure
  - Capital Expenditure By Geographic Area
  - Capital Expenditure By Geographic Area, 2005
  - R&D Expenditure
  - R&D Expenditure By Business Area
  - R&D Expenditure By Business Area, 2005
- Divisional Performance
  - Sales By Business Area
  - Sales By Business Area, 2005
  - Total Human Vaccine Sales
  - Breakdown of Vaccine Sales, 2005
- Geographic Performance
  - Total Net Sales By Geographic Area
  - Total Net Sales By Geographic Area, 2005
  - Total Assets By Geographic Area
  - Product Sales By Geographical Region
Company Strategy
- Mergers, Acquisitions and Divestitures
  - Mergers
  - Acquisitions
  - Divestitures
- Key Agreements
- Production
- Employees
  - Consolidated Employees By Geographic Area
  - Employees By Geographic Area, 2005
  - Consolidated Employees By Main Category Of Function
  - Consolidated Employees By Function, 2005
Product / R&D Overview
- Vaccines
- Key Products
  - Recent Product Launches
  - Discontinued Products
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D Projects
  - Cariporide (HOE 642)
  - Dynepo (HMR 4396)
  - SL 25.1039
  - SR 49059
  - SR 27897
- Sales Forecasts
  - Sales of Current Top Ten Products (2000A-2010E)
    - Pharmaceuticals
    - Vaccines
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas and Sales
Top Selling Products, 2005
R&D Pipeline

Cardiovascular / Thrombosis - Products
- Major Launched Products
- Aviator/Aprovel/Avapro/Avalide/CoAprovel
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Sales Forecast
- Aprovel sales (2000A-2010E)
- Delix/Tritace/Triatec
  - Sales
  - Key Markets/Indications.Formulations
  - Patents
  - Competitor Products
  - Sales Forecast
- Delix sales (2000A-2010E)
- Lovenox/Clexane
  - Sales
  - Key Markets/Indications/Formulations
  - Further development
  - Patents/Generic Competition/Lawsuits
  - Competitor Products
  - Sales Forecasts
- Lovenox Sales (2000A-2010E)
  - Clinical Trial Results
- Plavix/Iscover
  - Sales
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Further Development
  - Patents
  - Lawsuits - Aircoat
  - Lawsuits - Apotex and Ranbaxy
  - Safety Issues
  - Sales Forecast
  - Plavix sales (2000A-2010E)
    - Clinical Trial Results
- Cardiovascular / Thrombosis - R&D
  - Ataciguat (HMR1766)
  - AVE0118
  - AVE1231
  - AVE3247
  - AVE7688
  - AVE9488
  - Dronedarone
    - Clinical Trial Results
  - HMR1069
  - Idraparinux
  - Octaparine (AVE5026)
  - Otamixaban (XRP0673)
  - SL 65.0472
  - SR 123781
  - SSR 126517
  - SSR 149744
  - XRP0038 (NV1FGF)
- Cardiovascular / Thrombosis - Summary
  - Growth Potential
  - Limiting Factors
- Oncology - Products
  - Eloxatin
    - Sales
    - Key Markets/Indications/Formulations
    - Further Development
    - Patents/Lawsuits
    - Competitor Products
    - Sales Forecast
  - Eloxatin sales (2000A-2010E)
    - Clinical Trials Results
  - Fasturtec/Elitek
    - Key Markets/Indications/Formulations
    - Further Development
  - Taxotere
    - Sales
    - Key Markets/Indications/Formulations
    - Further Development
    - Patents
    - Competitor Products
    - Sales Forecast
  - Taxotere sales (2000A-2010E)
    - Clinical Trial Results
- Oncology - R&D
  - Alvocidib
  - AVE 0005
    - Studies with Regeneron
    - Clinical Trial Results
  - AVE 8062
  - AVE9633
  - CEP7055
  - SR 31747/SSR 125329
  - Tirazone
  - Uvidem
  - XRP6258
  - XRP9881
- Oncology - Summary
  - Growth Potential
  - Limiting Factors
- Central Nervous System - Products
  - Major Launched Products
  - Copaxone
    - Sales
    - Key Markets/Indications/Formulations
    - Further Development
    - Competitor Products
    - Sales Forecast
  - Copaxone Sales (2000A-2010E)
    - Clinical Trial Results
  - Depakine
    - Sales
    - Key Markets/Indications/Formulations
    - Sales Forecast
  - Depakine Sales (2000A-2010E)
  - Stilnox/Stilnoct/Ambien/Myslee
    - Sales
    - Key Markets/Indications/Formulations
    - Further Development
    - Patents/Lawsuits/Generic Competition
    - Safety Issues
    - Competitor Products
    - Sales Forecast
  - Stilnox Sales (2000A-2010E)
- Central Nervous System - R&D
  - Acomplia
  - AVE1625
  - AVE9897
  - Eplivanserin (SR 46349)
  - HP184
  - M100907
  - Saredutant (SR 48968)
  - SR 57667
  - SR 58611
  - SSR 125543
  - SSR 149415
  - SSR 180575
  - SSR 411298
  - SSR 504734
  - SSR 591813
  - Teriflunomide
  - Xaliproden (SR 57746)
- Central Nervous System - Summary
  - Growth Potential
  - Limiting Factors
- Metabolism / Diabetes - Products
  - Major Launched Products
  - Apidra
    - Further Development
    - Clinical Trial Results
  - Amaryl
    - Sales
    - Sales Forecast
    - Key Markets/Indications/Formulations
    - Generic Competition
    - Competitor Products
    - Sales Forecast
  - Amaryl Sales (2000A-2010E)
  - Lantus
    - Sales
    - Key Markets/Indications
    - Patents
    - Further Development
    - Patents/Lawsuits/Generic Competition
    - Competitor Products
    - Sales Forecast
  - Lantus sales (2000A-2010E)
    - Clinical Trial Results
- Metabolism / Diabetes - R&D
  - AVE0010 (ZP10)
  - AVE0847
  - AVE2268
  - AVE5530
  - AVE5376
  - AVE8134
  - SSR 162369
- Metabolism / Diabetes - Summary
  - Growth Potential
  - Limiting Factors
- Vaccines - Products
  - Vaccine Sales by Area
  - Vaccine Sales, 2005
  - Influenza
    - Sales
    - Key Products
    - Further Development
  - Polio/Whooping Cough/HIB
    - Sales
    - Key Products
    - Further Development
  - Adult booster
    - Sales
    - Key Products
  - Meningitis
    - Sales
    - Key Products
    - Further Development
    - Safety Issues
    - Clinical Trial Results
  - Travel Vaccines
    - Sales
    - Further Development
Vaccines - R&D
- Cytomegalovirus
- Dengue Fever Vaccine
  - Clinical Trial Results
- Flu Infants
- Flu Micro-Injection
- Flu Pandemia
  - Clinical Trial Results
- Gardasil
  - Clinical Trial Results
- HIV/AIDS Vaccines
- HR51
- Zostavax
Vaccines - Summary
- Growth Potential
- Limiting Factors
Respiratory / Allergy - Products
- Major Launched Products
- Allegra/Telfast
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Patents/Lawsuits/Generic Competition
  - Sales Forecast
- Allegra Sales (2000A-2010E)
- Alvesco
  - Key Markets/Indications/Formulations
  - Further Development
  - Clinical Trial Results
- Nasacort/Nasacort AQ/Nasacort HFA
  - Sales
  - Key Markets/Indications/Formulations
  - Sales Forecast
- Nasacort Sales (2000A-2010E)
Respiratory / Allergy - R&D
Arthritis / Osteoporosis - Products
- Major Launched Products
- Actonel
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Generic Competition/Lawsuits
  - Clinical Trial Results
  - Competitor Products
  - Sales Forecast
- Actonel Sales (2000A-2010E)
Arthritis / Osteoporosis - R&D
- AVE9897
- Icatibant
Genito-urinary - Products
- Major Launched Products
- Xatral
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
Genito-urinary - R&D
- SSR 240600
Anti-infective - Products
- Ketek
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
Anti-infective - R&D
- Ferroquine (SSR 97193)
- Picovir
- XRP2868
Other - Products
- Flisint
Other - R&D
- SR 121463
  - Clinical Trial Results
- SSR 126768
- SSR 150106
- SSR 240612
Internal Medicine - Summary

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

aaiPharma
- 11th January 2001
Acambis plc
- 28th April 1998
- 11th May 1999
Ajinomoto Co Inc
- 5th December 1997
Altana Pharma AG
- 15th October 1999
- 26th March 2001
Amgen
- 9th April 1998
Astellas Pharma Inc
- 12th July 1999
- 14th November 2001
- 19th April 2002
- 13th February 2003
- 20th November 2003
- 16th December 2005
- 12th April 2006
Astex Technology
- 25th March 2002
- 8th June 2004
AstraZeneca
- 17th June 2002
Atrix Laboratories Inc
- 9th January 2001
- 16th March 2004
Becton Dickinson and Company (BD)
- 12th April 1999
- 21st December 2005
Bristol-Myers Squibb
- 8th June 2001
- 21st March 2006
Celera Genomics/Axys Pharmaceuticals
- 18th December 1998
Cephalon Inc
- 20th December 2001
- 8th January 2002
Chiron Corporation
- 4th July 2000
Ciphergen Biosystems
- 7th February 2006
Coley Pharmaceutical Group Inc
- 6th August 2001
Crucell NV
- 24th January 2003
- 7th January 2004
Daiichi Sankyo
July 1993
- 13th February 2003
- 5th July 2005
Dainippon Sumitomo Pharma
- 1989
Debiopharm SA
- 27th August 2002
Eli Lilly
- 23rd October 2000
French Ministry of Health
- 10th November 2005
GlaxoSmithKline
- 12th February 1998
- 23rd September 1998
IDM Pharma Inc
- 22nd January 2002
- 19th February 2002
- 4th December 2002
ImmunoGen Inc
- 31st July 2003
- 31st August 2005
King Pharmaceuticals Inc
- 22nd December 1998
- 31st December 2002
Millennium Pharmaceuticals Inc
- 13th August 2001
- Inflammation agreement
- Technology development agreement
- Technology transfer agreement
Nabi Biopharmaceuticals
- 26th April 2006
Novo Nordisk
- 31st January 2001
Pfizer
- 26th January 2001
- 14th October 2002
- 1st March 2006
Prasco Laboratories
- 25th July 2005
Procter & Gamble
- 5th May 1997
- 8th October 2004
Regeneron Pharmaceuticals Inc
- 10th January 2005
- 22nd December 2005
Roche/Genentech
- 6th December 2000
- 16th March 2006
SAS Institute
- 25th February 2004
Shionogi
Teva Pharmaceutical Industries Ltd
- September 1993
- 14th February 2001
US Government
- April 2005
- September 2005
VaxGen Inc
- 19th April 1998
Zealand Pharmaceuticals A/S
- 25th June 2003
Licensing
Co-Promotion/Co-Marketing

APPENDIX 4 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

Subsidiaries
- Major Fully-Consolidated Subsidiaries
- Major Associates
Joint Ventures

sanofi-aventis: Pipeline, Products, Performance, Potential

Table of Contents

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

APPENDIX 4 - INFRASTRUCTURE

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

APPENDIX 6 - PRODUCT INDEX